- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01379274
A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes
A Phase II Trial of Revlimid® (Lenalidomide) and Low Dose Vidaza® (Azacitidine) in Patients With Low - Intermediate-1 Risk Myelodysplastic Syndromes
This phase II study will evaluate the safety and efficacy of combining two active agents;Revlimid® (lenalidomide) and low dose Vidaza® (azacitidine) for the treatment of patients with low to intermediate-1 MDS excluding patients with 5 q deletion. The rationale for adding Vidaza® (azacitidine) after 3 months of revlimid monotherapy is that combination therapy will result in higher response rates, and potentially longer response duration than that achieved with either agent.
STUDY OBJECTIVES:
Primary:
To determine the safety and tolerability of the combination of Revlimid® (lenalidomide) and low dose Vidaza® (azacitidine) in patients with low - intermediate-1 risk MDS non 5 q deletion who have not responded after 3 months of Revlimid® (lenalidomide) monotherapy
Secondary:
To determine the response rate in patients with low - intermediate-1 risk MDS non 5 q deletion receiving Revlimid® (lenalidomide) in combination with low dose Vidaza® (azacitidine), as defined by the IWG 2006 Revised Response Criteria
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Eligibility criteria
- Understand and voluntarily sign an informed consent form.
- Age 18 years at the time of signing the informed consent form.
- Able to adhere to the study visit schedule and other protocol requirements.
Diagnosis of low- or intermediate-1-risk IPSS (see Appendix III) MDS without an abnormality of chromosome 5 involving a deletion between bands q31 and q33.
Pathologic diagnosis via pathology performed at Rush University Medical Center or made available to Rush from outside institution.
- Prior treatment with < 3 cycles (84 days) of Revlimid® (lenalidomide) are eligible for enrollment regardless of response.
- ECOG performance status of 2 at study entry (see Appendix II).
- Disease free of prior malignancies for > 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "insitu" of the cervix or breast.
- Serum bilirubin levels < 1.5 times the upper limit of the normal range for the laboratory (ULN). Higher levels are acceptable if these can be attributed to active hemolysis or ineffective erythropoiesis.
- Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) levels < 2 x ULN.
- Serum creatinine levels < 1.5 x ULN
- Absolute neutrophil count > 1000/mm³
- Platelet count > 30,000/mm³
- All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: Patients with low to Int-1 risk MDS
- ECOG performance status of < 2 at study entry (see Appendix II).
- Disease free of prior malignancies for 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "insitu" of the cervix or breast.
- Serum bilirubin levels < 1.5 times the upper limit of the normal range for the laboratory (ULN). Higher levels are acceptable if these can be attributed to active hemolysis or ineffective erythropoiesis.
- Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) levels < 2 x ULN.
- Serum creatinine levels 1.5 x ULN
- Absolute neutrophil count > 1000/mm³
- Platelet count > 30,000/mm³
- All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.
- Females of childbearing potential (FCBP)† must have a negative serum or urine
Exclusion Criteria:
- Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
- Pregnant or breast feeding females. Lactating females must agree not to breast feed while taking Revlimid® (lenalidomide).
- Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
- Use of any other experimental drug or therapy within 28 days of baseline.
- Known hypersensitivity to lenalidomide, azacitidine, or mannitol.
- Any prior use of Vidaza® (azacitidine).
- Prior use of Revlimid® (lenalidomide) for more than 84 days (three 28 day cycles).
- Concurrent use of other anti-cancer agents or treatments.
- Known positive for HIV or infectious hepatitis, type B or C.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: lenalidomide and azacitidine combination
Lenalidomide and azacitidine combination to be utilized in patients who did not respond to 3 months of lenalidomide monotherapy.
|
lenalidomide 10 mg will be administered orally on Days 1-28 of each 28-day cycle. Patients who fail to achieve an erythroid response per 2006 IWG criteria after 3 cycles of monotherapy will receive lenalidomide at the same dose administered in cycle 3 and low-dose azacitidine25 mg/m2 subcutaneously (SC) or intravenously (IV) for 5 days (on Days 1-5) of every 28-day cycle. Patients who fail to respond (2006 IWG criteria) after receiving two cycles of combination therapy will receive lenalidomide at the same dose administered in Cycle 3 and azacitidine 50 mg/m2 SC or IV given daily on Days 1-5 of each 28-day cycle, if no grade 4 toxicity developed or no delay greater than 2 weeks in starting a new cycle was experienced during the first 2 cycles of combination therapy.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability of Revlimid and Azacitidine Combination
Time Frame: Study was closed and outcome unable to be measured.
|
To determine the number of subjects who develop grade 4 toxicity while on combination therapy.
|
Study was closed and outcome unable to be measured.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jamile M Shammo, MD, Rush University Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Bone Marrow Diseases
- Hematologic Diseases
- Precancerous Conditions
- Myelodysplastic Syndromes
- Preleukemia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Lenalidomide
- Azacitidine
Other Study ID Numbers
- MDS 2008-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MDS
-
Assiut UniversityUnknown
-
Groupe Francophone des MyelodysplasiesNovartisUnknown
-
Zhejiang Provincial Hospital of TCMUnknown
-
University Hospital TuebingenRecruiting
-
Montefiore Medical CenterRecruitingAML | MDSUnited States
-
The Second Hospital of Shandong UniversityNot yet recruiting
-
Groupe Francophone des MyelodysplasiesAstex Pharmaceuticals, Inc.Active, not recruiting
-
Rigshospitalet, DenmarkRecruiting
-
GWT-TUD GmbHRecruiting
-
M.D. Anderson Cancer CenterRecruiting
Clinical Trials on Lenalidomide and azacitidine combination
-
Duke UniversityCelgeneTerminatedFollicular Lymphoma | Marginal Zone LymphomaUnited States
-
Nordic MDS GroupUnknownMyelodysplastic Syndrome | Acute Myelogenous LeukemiaSweden
-
The First Affiliated Hospital of Soochow UniversityEnrolling by invitationMyelodysplastic/Myeloproliferative Neoplasms | AdultChina
-
Groupe Francophone des MyelodysplasiesCelgeneCompletedLenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q (GFM-AZA-REV-09)Myelodysplastic SyndromesFrance
-
Mikkael Sekeres MDNational Cancer Institute (NCI)CompletedMyelodysplastic Syndromes | LeukemiaUnited States
-
First Affiliated Hospital of Zhejiang UniversityXiangya Hospital of Central South University; Second Affiliated Hospital, School... and other collaboratorsRecruitingHematologic Malignancy | Stem Cell Transplant ComplicationsChina
-
The First Affiliated Hospital of Soochow UniversityThe Second People's Hospital of Huai'an; First Affiliated Hospital Bengbu Medical... and other collaboratorsRecruiting
-
The First Affiliated Hospital of Xiamen UniversityShanxi Province Cancer Hospital; Sun Yat-sen University; Jiangsu Provincial People... and other collaboratorsRecruiting
-
ZePing ZhouGuizhou Provincial People's Hospital; Second Xiangya Hospital of Central South... and other collaboratorsRecruiting
-
Columbia UniversityCelgene Corporation; Schering-PloughUnknownSoft Tissue Sarcoma | MesotheliomaUnited States